Illumina (NASDAQ: ILMN)
Illumina Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Illumina Company Info
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
News & Analysis
Tariff and Trade Investigation Tracker
A one-stop shop to track all the tariff and trade action from the Trump administration
Why Illumina Stock Got Mashed on Monday
Why Illumina Stock Is Sinking Today
Investing in Genomics Stocks
Why Illumina Stock Plummeted Today
Illumina Surpasses EPS Expectations
Illumina exhibited stable performance in its latest earnings, meeting revenue estimates while navigating rising expenses and legal costs.
Investing in Cancer Stocks
Learn about some of the leading cancer stocks in the U.S stock market this year.
These Are Billionaires’ Favorite Healthcare Stocks
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
Valuation
Podcast Episodes
Illumina CEO Steps Down; Grail Soap Opera Continues
And we interview Anjay Nagpal, host of the podcast "Brokers, Bagmen, and Moles."
Why Illumina Could Be a Health Tech Powerhouse for Your Portfolio
The sky is the limit for the leader in DNA sequencing.
Our Top Stock Ideas in Silicon Valley’s Biggest Bet in Healthcare
The Fools reveal three stock ideas for investors interested in personalized medicine and precision oncology.
Better Buy: Illumina or Gilead Sciences?
We’re pitting off gene sequencing giant Illumina against giant biotech Gilead Sciences to see which company is the better buy for long-term investors.
Earnings Transcripts
Illumina, inc (ILMN) Q3 2021 Earnings Call Transcript
ILMN earnings call for the period ending September 30, 2021.
Illumina, inc (ILMN) Q2 2021 Earnings Call Transcript
ILMN earnings call for the period ending June 30, 2021.
Illumina Inc (ILMN) Q1 2021 Earnings Call Transcript
ILMN earnings call for the period ending March 31, 2021.
Illumina Inc (ILMN) Q4 2020 Earnings Call Transcript
ILMN earnings call for the period ending January 3, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.